Canakinumab is a recombinant, fully human monoclonal antibody that targets interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. Belonging to the IgG1/κ isotype subclass, canakinumab functions by binding specifically to IL-1β and neutralizing its activity. It inhibits the interaction of IL-1β with its receptors, effectively blocking downstream inflammatory signaling. Importantly, it does not bind to other related molecules such as IL-1α or the IL-1 receptor antagonist (IL-1ra), ensuring selectivity in its mechanism of action.
In clinical and research settings, canakinumab is primarily used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare autoinflammatory disorders. In these diseases, dysregulation of the NLRP3 gene results in overactivation of the protein cryopyrin, which in turn leads to excessive IL-1β activity and chronic inflammation. By inhibiting IL-1β, canakinumab helps restore immune balance and reduce disease symptoms such as fever, rash, joint pain, and fatigue.
Canakinumab has broad potential beyond CAPS and is being studied for its role in other inflammatory and autoimmune conditions, as well as cardiovascular diseases where IL-1β plays a contributing role. Its high specificity and durable effect on IL-1β make it a valuable therapeutic and research tool for understanding cytokine-driven inflammation and for developing targeted anti-inflammatory strategies.
This product is manufactured in Turkey by Matriks Biotek.